Chromocell Therapeutics logo

Chromocell TherapeuticsNYSE American: CHRO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 February 2024

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$3.78 M
-86%vs. 3y high
10%vs. sector
-vs. 3y high
-vs. sector
-119%vs. 3y high
7%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 23 min ago
$0.66+$0.07(+11.24%)

Dividend

No data over the past 3 years
$0.00-$1.69 M

Analysts recommendations

Institutional Ownership

CHRO Latest News

Chromocell Announces Amendment to Stock Repurchase Plan
globenewswire.com24 October 2024 Sentiment: POSITIVE

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has authorized an amendment (the “Amendment”) to the Company's existing stock repurchase plan (as amended, the “Repurchase Plan”) to increase the total value of shares of Chromocell's common stock (“Common Stock”) available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000.

Chromocell to Participate in Life Sciences Investor Forum September 19th
globenewswire.com16 September 2024 Sentiment: POSITIVE

FREEHOLD, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel, CEO, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th 2024.

Chromocell Announces Stock Repurchase Plan
globenewswire.com07 August 2024 Sentiment: POSITIVE

FREEHOLD, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “Board of Directors”) has authorized a stock repurchase plan (the “Repurchase Plan”) of up to $250,000 of Chromocell's common stock (“Common Stock”), which represents approximately 23% of the non-affiliate float based on the closing price of the Company's Common Stock as of August 6, 2024. The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the Board of Directors at any time.

Chromocell to Participate in the Virtual Investor Lunch Break Series
globenewswire.com15 July 2024 Sentiment: POSITIVE

Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET Live webcast with Frank Knuettel II, Chief Executive Officer and Chief Financial Officer, on Thursday, July 18th at 12:00 PM ET

Paycom Announces Promotions of Randy Peck to COO, Jennifer Kraszewski to CHRO and Matt Paque to CLO
businesswire.com31 May 2024 Sentiment: POSITIVE

OKLAHOMA CITY--(BUSINESS WIRE)--Paycom Software, Inc. (NYSE: PAYC) (“Paycom” or the “Company”), a leading provider of comprehensive, cloud-based human capital management software, announced that Randy Peck, a 20-year Paycom veteran, has been appointed to serve as Paycom's Chief Operating Officer, while Matt Paque and Jennifer Kraszewski have been promoted to Chief Legal Officer and Chief Human Resources Officer, respectively. “These promotions align with our ambition to continue to help Paycom.

PROLOGIS' NEKRITZ AND MCKEOWN TO RETIRE; NEW CLO AND CHRO ANNOUNCED
prnewswire.com22 May 2024 Sentiment: POSITIVE

Briones and Carey to join company's executive committee on Jan. 1, 2025 SAN FRANCISCO , May 22, 2024 /PRNewswire/ -- Prologis (NYSE: PLD) today announced Ed Nekritz and Colleen McKeown will retire as chief legal officer and chief human resources officer, effective January 1, 2025.  Current Deputy General Counsel Deborah Briones and Senior Vice President of Human Resources Nathaalie Carey will succeed Nekritz and McKeown.

What type of business is Chromocell Therapeutics?

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

What sector is Chromocell Therapeutics in?

Chromocell Therapeutics is in the Healthcare sector

What industry is Chromocell Therapeutics in?

Chromocell Therapeutics is in the Biotechnology industry

What country is Chromocell Therapeutics from?

Chromocell Therapeutics is headquartered in United States

When did Chromocell Therapeutics go public?

Chromocell Therapeutics initial public offering (IPO) was on 16 February 2024

What is Chromocell Therapeutics website?

https://www.chromocell.com

Is Chromocell Therapeutics in the S&P 500?

No, Chromocell Therapeutics is not included in the S&P 500 index

Is Chromocell Therapeutics in the NASDAQ 100?

No, Chromocell Therapeutics is not included in the NASDAQ 100 index

Is Chromocell Therapeutics in the Dow Jones?

No, Chromocell Therapeutics is not included in the Dow Jones index

When was Chromocell Therapeutics the previous earnings report?

No data

When does Chromocell Therapeutics earnings report?

Next earnings report date is not announced yet